Drug Profile
Haematopoietic progenitor kinase 1 (MAP4K1) inhibitor - APC Therapeutics/Glenmark Pharmaceuticals Ltd
Alternative Names: GRC 5XXX; HPK1 inhibitor-Glenmark Pharmaceuticals LtdLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Advanced Proteome Therapeutics
- Developer Glenmark Pharmaceuticals Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Cancer in India (PO)
- 10 Apr 2021 Pharmacodynamic and pharmacokinetic data from a preclinical study in cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021) (3566395
- 08 Jan 2020 Glenmark Pharmaceuticals Ltd plans a phase I trial in Cancer in the second half of 2020 (Glenmark Pharmaceuticals Ltd pipeline, January 2020)